Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03858543 · ClinicalTrials.gov registry record · Early Phase 1
Fractional Laser Assisted Delivery of Sculptra® for the Treatment of Striae
A Early Phase 1 study of Striae Distensae, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03858543 is a Early Phase 1 study of Striae Distensae that has completed, run by Henry Ford Health System. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03858543, a Early Phase 1 study of Striae Distensae, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the efficacy of treatment of striae distensae using the combined modality of fractional laser and poly-L lactic acid (Sculptra).
Conditions Studied
Interventions
- DRUG Poly-L Lactic Acid
- DEVICE Fractional laser treatment
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2021-01-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03858543
The ClinicalTrials.gov registry entry for NCT03858543 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Striae Distensae appearing as the primary indexed condition, and to 2 interventions - of which Poly-L Lactic Acid is the first listed.
NCT03858543 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03858543 about?
NCT03858543 is a clinical study titled "Fractional Laser Assisted Delivery of Sculptra® for the Treatment of Striae". This study evaluates the efficacy of treatment of striae distensae using the combined modality of fractional laser and poly-L lactic acid (Sculptra).
What is the current status of trial NCT03858543?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-07-15. Estimated completion is 2021-01-31.
What conditions does trial NCT03858543 study?
This clinical trial studies the following conditions: Striae Distensae.
What interventions are being tested in trial NCT03858543?
The interventions under investigation include: Poly-L Lactic Acid (DRUG), Fractional laser treatment (DEVICE).
Who is sponsoring clinical trial NCT03858543?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03858543 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.